# Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

> **NCT01111123** · PHASE4 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 55 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)
- **DRUG:** Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment

## Key facts

- **NCT ID:** NCT01111123
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2016-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111123, "Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01111123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*